Fatemeh Saadatpour, Yan-Duo Wang, Saman A Mohammed, Gang Ding, Fatemeh Mohammadipanah
{"title":"Hypoglycemic activity and metabolite diversity of Archangium sp. UTMC 4535 with the first report on magnodelavin biosynthesis by bacteria.","authors":"Fatemeh Saadatpour, Yan-Duo Wang, Saman A Mohammed, Gang Ding, Fatemeh Mohammadipanah","doi":"10.1016/j.bioorg.2024.108053","DOIUrl":null,"url":null,"abstract":"<p><p>Diabetes has been declared an epidemy by the World Health Organization and represents a significant metabolic comorbidity. Given the promising pharmaceutical activities of myxobacterial secondary metabolites, we investigated the inhibitory potential of compounds from the soil myxobacterium Archangium sp. UTMC4535, leading to the identification of magnodelavin C, a guaiane sesquiterpene lactone.This study details the isolation, structural elucidation, and biological evaluation of magnodelavin C against enzymes associated with type 2 diabetes (T2D), specifically alpha (α)-glucosidase and glucose transferase, utilizing molecular docking and in vitro assessments. Docking studies identified five binding pockets in α-glucosidase, with magnodelavin C displaying favorable binding scores between -5.4 to -6.7 kcal/mol. Experimental results indicated that magnodelavin C inhibited α-glucosidase approximately three times more effectively than the crude extract, exhibiting potency comparable to the standard drug acarbose. Furthermore, magnodelavin C demonstrated an inducing effect on glucose transport with an average uptake percentage of 80 % compared to the drug control. MTT assay results confirmed that magnodelavin C exhibited no cytotoxic effects on the L929 fibroblast cell line at any tested concentration, contrasting with acarbose's approximately 25 % mortality rate. This compound also demonstrated advantageous drug-likeness properties and human intestinal absorption while exhibiting lower toxicity compared to acarbose. The discovery of magnodelavin C highlights the rich diversity of secondary metabolites produced by myxobacteria and their potential applications in drug discovery.</p>","PeriodicalId":257,"journal":{"name":"Bioorganic Chemistry","volume":"154 ","pages":"108053"},"PeriodicalIF":4.5000,"publicationDate":"2024-12-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Bioorganic Chemistry","FirstCategoryId":"92","ListUrlMain":"https://doi.org/10.1016/j.bioorg.2024.108053","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"BIOCHEMISTRY & MOLECULAR BIOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Diabetes has been declared an epidemy by the World Health Organization and represents a significant metabolic comorbidity. Given the promising pharmaceutical activities of myxobacterial secondary metabolites, we investigated the inhibitory potential of compounds from the soil myxobacterium Archangium sp. UTMC4535, leading to the identification of magnodelavin C, a guaiane sesquiterpene lactone.This study details the isolation, structural elucidation, and biological evaluation of magnodelavin C against enzymes associated with type 2 diabetes (T2D), specifically alpha (α)-glucosidase and glucose transferase, utilizing molecular docking and in vitro assessments. Docking studies identified five binding pockets in α-glucosidase, with magnodelavin C displaying favorable binding scores between -5.4 to -6.7 kcal/mol. Experimental results indicated that magnodelavin C inhibited α-glucosidase approximately three times more effectively than the crude extract, exhibiting potency comparable to the standard drug acarbose. Furthermore, magnodelavin C demonstrated an inducing effect on glucose transport with an average uptake percentage of 80 % compared to the drug control. MTT assay results confirmed that magnodelavin C exhibited no cytotoxic effects on the L929 fibroblast cell line at any tested concentration, contrasting with acarbose's approximately 25 % mortality rate. This compound also demonstrated advantageous drug-likeness properties and human intestinal absorption while exhibiting lower toxicity compared to acarbose. The discovery of magnodelavin C highlights the rich diversity of secondary metabolites produced by myxobacteria and their potential applications in drug discovery.
期刊介绍:
Bioorganic Chemistry publishes research that addresses biological questions at the molecular level, using organic chemistry and principles of physical organic chemistry. The scope of the journal covers a range of topics at the organic chemistry-biology interface, including: enzyme catalysis, biotransformation and enzyme inhibition; nucleic acids chemistry; medicinal chemistry; natural product chemistry, natural product synthesis and natural product biosynthesis; antimicrobial agents; lipid and peptide chemistry; biophysical chemistry; biological probes; bio-orthogonal chemistry and biomimetic chemistry.
For manuscripts dealing with synthetic bioactive compounds, the Journal requires that the molecular target of the compounds described must be known, and must be demonstrated experimentally in the manuscript. For studies involving natural products, if the molecular target is unknown, some data beyond simple cell-based toxicity studies to provide insight into the mechanism of action is required. Studies supported by molecular docking are welcome, but must be supported by experimental data. The Journal does not consider manuscripts that are purely theoretical or computational in nature.
The Journal publishes regular articles, short communications and reviews. Reviews are normally invited by Editors or Editorial Board members. Authors of unsolicited reviews should first contact an Editor or Editorial Board member to determine whether the proposed article is within the scope of the Journal.